in 1995, the firm was acquired by Rhone-Poulanc. Applied Immune Sciences develops, manufactures, and delivers innovative cell and gene therapy products designed to enhance and restore the immune system in immune-related conditions such as bone marrow transplantation and cancer, autoimmune, and infectious diseases. AIS entered into a strategic alliance with Rhône-Poulenc Rorer in 1993 and is now affiliated with the newly formed RPR division, RPR Gencell. Through RPR Gencell, AIS has access to a network of 14 commercial, academic, and other institutions in the biotechnology field. AIS products are now in human clinical trials for bone marrow transplantation and the treatment of AIDS an
